EGFR and silicosis: Inhibition of p-EGFR and p-SYK by gefitinib and fostamatinib were found to effectively ameliorated the progression of silicosis via inhibiting p-EGFR mediated fibronectin production in fibroblasts and p-SYK mediated pro-inflammatory cytokines synthesis in macrophages.